Role of targeted therapy in metastatic colorectal cancer

doi:10.4251/wjgo.v8.i9.642

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10310)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

967

WORD

337

HTML

6575

Tables (1-4)

146

Sum=8025

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

964

Download

1321

Sum=2285

Sep 15, 2016 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (72)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Sep 15, 2016; 8(9): 642-655
Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.642

Table 1 Clinical trials of anti-angiogenic therapies in metastatic colorectal cancer

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
First-line chemotherapy
AVF2017g	IFL + Bevacizumab	402	44.8%	10.6	20.3
BICC-C	FOLFIRI + Bevacizumab	57	57.9%	11.2	28.0
NO16966	FOLFOX/CapeOX + Bevacizumab	699	38%	9.4	21.3
TREE-1/2	FOLFOX + Bevacizumab	71	52%	9.9	26.1
CAIRO2	CapeOX + Bevacizumab	378	50%	10.7	20.3
SOFT	SOX + Bevacizumab	256	61.5%	11.7	29.6
TRIBE	FOLFOXIRI + Bevacizumab	252	65.1%	12.1	31.0
AVEX¹	Capecitabine + Bevacizumab	140	19.3%	9.1	20.7
Second-line, salvage-line chemotherapy, or beyond progression
E3200	FOLFOX + Bevacizumab	286	22.7%	7.3	12.9
ML18147	Chemotherapy + Bevacizumab	410	5.4%	5.7	11.2
C-TASK FORCE	TAS-102 + Bevacizumab	25	4.0%	5.6	11.2
VELOUR	FOLFIRI + Aflibercept	612	19.8%	6.9	13.5
RAISE	FOLFIRI + Ramucirumab	536	13.4%	5.7	13.3
CORRECT	Regorafenib	505	1.0%	1.9	6.4

¹AVEX trial enrolled mCRC patients aged 70 years and older. ORR: Objective response rate; PFS: Progression-free survival; IFL: Bolus 5-fluorouracil/leucovorin/irinotecan; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin; CapeOX: Capecitabine/oxaliplatin; SOX: S-1 (tegafur/gimeracil/oteracil)/oxaliplatin; FOLFOXIRI: Infusional 5-fluorouracil/leucovorin/irinotecan/oxaliplatin; OS: Overall survival; mCRC: Metastatic colorectal cancer.

Citation: Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655
URL: https://www.wjgnet.com/1948-5204/full/v8/i9/642.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i9.642